• Explore /
  • Poster
  • / A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.

A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.

Abstract Poster

Authors

null

Steven G. DuBois

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA

Steven G. DuBois , Jill D. Kremer , Bram De Wilde , Chad Jacobsen , Isabelle Aerts , Yael P. Mosse , John M. Maris , Andrew Lithio , Andreas Gosberg , C.L. Banks , Courtney Tate , Michele Dowless , Xueqian Gong , Louis Stancato , Katherine M. Bell-McGuinn , Julie R. Park , Andrew DJ Pearson , Araz Marachelian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

NCT04106219

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS10561)

DOI

10.1200/JCO.2020.38.15_suppl.TPS10561

Abstract #

TPS10561

Poster Bd #

448

Abstract Disclosures

Similar Posters

First Author: Kelly C. Goldsmith

First Author: Damon R. Reed

First Author: Araz Marachelian

First Author: Theodore Willis Laetsch